StockNews.AI
CNC
StockNews.AI
39 days

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Centene

1. Faruqi & Faruqi investigates claims against Centene for misleading statements. 2. A class action was filed; September 8, 2025 is the lead plaintiff deadline. 3. Centene's stock plummeted 40.4% after withdrawing its 2025 guidance. 4. Investors question the company's growth in the Health Insurance Marketplace. 5. The firm's investigation highlights potential enrollment and morbidity rate issues.

5m saved
Insight
Article

FAQ

Why Bearish?

The stock's 40.4% drop after guidance withdrawal signals declining investor confidence, similar to past instances when companies misled investors, leading to severe price drops.

How important is it?

Legal actions against Centene directly affect investor sentiment and stock performance, evidenced by the significant price drop following the guidance withdrawal.

Why Short Term?

The immediate aftermath of the news will likely result in continued volatility, as investors reassess Centene's financial health.

Related Companies

UNHANTMCNC
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Centene To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Centene between December 12, 2024 and June 30, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Centene Corporation (“Centene” or the “Company”) (NYSE: CNC) and reminds investors of the September 8, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Centene's enrollment and morbidity rates. Investors began to question the veracity of defendants' public statements on July 1, 2025, when Centene issued a press release withdrawing 2025 guidance. Particularly, following an analysis of the 2025 Health Insurance Marketplace, Centene's overall market growth across 22 states, or 72% of the Company's marketplace membership, was lower than expected. In pertinent part, the Company stated that this preliminary analysis resulted in a reduction of its previously issued guidance to approximately $1.8 billion or an adjusted diluted EPS of $2.75. Following this news, Centene's common stock declined dramatically, from a closing market price of $56.65 per share on July 1, 2025, Centene's stock price fell to $33.78 per share on July 2, 2025, a decline of 40.4%. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.   Faruqi & Faruqi, LLP also encourages anyone with information regarding Centene’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Centene Corporation class action, go to www.faruqilaw.com/CNC or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4c96193e-9e8a-4e5d-878a-3e41b441e24a

Related News